左卡尼汀联合甘利欣治疗非酒精性脂肪性肝病临床疗效观察
|
摘要
目的:评价左卡尼汀联合甘利欣注射液治疗非酒精性脂肪性肝病的临床疗效。
方法:100例非酒精性脂肪性肝病患者随机分为两组,治疗组62例,对照组38例。治疗组给予左卡尼汀1 000 mg和甘利欣150 mg静脉滴注,对照组甘利欣150 mg,每天1次连续4周。治疗结束后复查B超、肝功能和血脂水平。
结果:治疗后两组病例肝功能酶学指标均较治疗前显著性下降(P < 0.01),但两组间无显著性差异(P > 0.05)。治疗组血清甘油三酯(TG)和胆固醇(TC)水平分别为(2.50±1.44)和(4.98±2.12)mmol/L,较治疗前显著性下降(P < 0.01);而对照组TG和TC水平治疗前、后无显著性差异(P > 0.05)。治疗组B超检查脂肪肝声像图消退率58.1%,明显优于对照组的28.9%(P < 0.05)。治疗组血脂改善总有效率96.7%,显著高于对照组的44.7% (P < 0.05)。
结论:左卡尼汀联合甘利欣治疗非酒精性脂肪性肝病,对改善肝功能和降低血脂有确切疗效。
Objective: Fatty liver is a condition of hepatic steatosis caused by many risk factors and may progress to liver fibrosis and cirrhosis. Thus, treatment should be given for patients who are at risk of developing severe liver disease. However, the management of fatty liver is less than certain. The aim of this prospective study was to evaluate the therapeutic effects of L-Carnitine combined with Glycyrrhiazte diammonium in the treatment of nonalcoholic fatty liver disease (NAFLD).
Methods: A total of 100 patients with NAFLD demonstrated by color Doppler ultrasound examination were randomized divided into two groups. The treatment group (n = 62) was intravenously given L-Carnitine 1 000 mg and Glycyrrhiazte diammonium 150 mg once daily for 4 weeks. The control group (n = 38) was treated with Glycyrrhiazte diammonium only. After 4 weeks of treatment, serum transaminase and lipid levels, and liver ultrasonography were repeated.
Results: The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly decreased after treatment with Glycyrrhiazte diammonium combined with or without L-Carnitine, but there were no significant differences between the two groups. Serum triglyceride (TG) and total cholesterol (TC) levels were (2.50±1.44) and (4.98±2.12) mmol/L respectively in the patients after treatment with L-Carnitine and Glycyrrhiazte diammonium, which were significantly lower than those prior to treatment (P < 0.01). No significant changes in serum levels of TG and TC were observed before and after treatment in the control group. Ultrasonography showed resolution of fatty liver in 58.1% of patients treated with L-Carnitine and Glycyrrhiazte diammonium, which were significantly higher than 28.9% in the control group (P < 0.05). The total effective rate for decreasing serum lipid level in treatment group was 96.7%, which was significantly higher than 44.7% in control group.
Conclusions: L-Carnitine in combination with Glycyrrhiazte diammonium has a reliable therapeutic effect on NAFLD in improving liver function and decreasing serum lipid level.
方法:100例非酒精性脂肪性肝病患者随机分为两组,治疗组62例,对照组38例。治疗组给予左卡尼汀1 000 mg和甘利欣150 mg静脉滴注,对照组甘利欣150 mg,每天1次连续4周。治疗结束后复查B超、肝功能和血脂水平。
结果:治疗后两组病例肝功能酶学指标均较治疗前显著性下降(P < 0.01),但两组间无显著性差异(P > 0.05)。治疗组血清甘油三酯(TG)和胆固醇(TC)水平分别为(2.50±1.44)和(4.98±2.12)mmol/L,较治疗前显著性下降(P < 0.01);而对照组TG和TC水平治疗前、后无显著性差异(P > 0.05)。治疗组B超检查脂肪肝声像图消退率58.1%,明显优于对照组的28.9%(P < 0.05)。治疗组血脂改善总有效率96.7%,显著高于对照组的44.7% (P < 0.05)。
结论:左卡尼汀联合甘利欣治疗非酒精性脂肪性肝病,对改善肝功能和降低血脂有确切疗效。
Objective: Fatty liver is a condition of hepatic steatosis caused by many risk factors and may progress to liver fibrosis and cirrhosis. Thus, treatment should be given for patients who are at risk of developing severe liver disease. However, the management of fatty liver is less than certain. The aim of this prospective study was to evaluate the therapeutic effects of L-Carnitine combined with Glycyrrhiazte diammonium in the treatment of nonalcoholic fatty liver disease (NAFLD).
Methods: A total of 100 patients with NAFLD demonstrated by color Doppler ultrasound examination were randomized divided into two groups. The treatment group (n = 62) was intravenously given L-Carnitine 1 000 mg and Glycyrrhiazte diammonium 150 mg once daily for 4 weeks. The control group (n = 38) was treated with Glycyrrhiazte diammonium only. After 4 weeks of treatment, serum transaminase and lipid levels, and liver ultrasonography were repeated.
Results: The serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly decreased after treatment with Glycyrrhiazte diammonium combined with or without L-Carnitine, but there were no significant differences between the two groups. Serum triglyceride (TG) and total cholesterol (TC) levels were (2.50±1.44) and (4.98±2.12) mmol/L respectively in the patients after treatment with L-Carnitine and Glycyrrhiazte diammonium, which were significantly lower than those prior to treatment (P < 0.01). No significant changes in serum levels of TG and TC were observed before and after treatment in the control group. Ultrasonography showed resolution of fatty liver in 58.1% of patients treated with L-Carnitine and Glycyrrhiazte diammonium, which were significantly higher than 28.9% in the control group (P < 0.05). The total effective rate for decreasing serum lipid level in treatment group was 96.7%, which was significantly higher than 44.7% in control group.
Conclusions: L-Carnitine in combination with Glycyrrhiazte diammonium has a reliable therapeutic effect on NAFLD in improving liver function and decreasing serum lipid level.
引文
1 范建高. 脂肪肝与肝纤维化的关系及其机制. 国外医学·消化系疾病分册,1997; 17(2):92 ~ 95
2 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊断标准.中华肝脏病杂志,2003; 11(2):71
3 范建高,曾民德. 非酒精性脂肪性肝病的分类及其诊断策略.中华肝脏病杂志,2003;11(2):127-128
4 Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999,107:450-455
5 Fan C-Y, Pan J, Usuda N, et al. Steatohepatitis,spontaneous peroxisone proliferation and liver tumours in mice prolixferatoractivated receptor alpha natural ligand metabolism.J Biol Chem,1998,273:15639-15645
6 Tokita H, Murai S, Kamitsukasa H, et al. In fluence of TT virus on the histopathological features of nonalcoholic fatty liver disease. Hepatol Res,2001,19(3):197-211
7 Tolba RH, Putz U, Decker D, et al. L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation. Transplantation, 2003; 76(12):1681 ~ 1686
8 杨丽蓉,徐晓玉. 甘利欣的药理作用与临床应用. 中国医院用药评价与分析,2003; 3(3):191 ~ 192
9 Furuno T, Kanno,Arita K,et al . Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol,2001;62(8):1037-1046.
10 Gulewitsch W,Krimberg R.Zur Kenntins der Extraktivstoffe der muskeln.Ueber bas Carnitin.Hoppe-Seyler’s Zeitschrift f.Physiol.Chemie,1905;45:326-330.
11 Frankel G. Caritine Book:Vitamin and Hormenes.Academic Press,New York,1957;XV:73-118.
12 Fritz IB.Carnitine and its Role in Fatty Acid Metabolism.Advances in Lipid Research,1963;285-334.
13 Hochalter JB.Carnitine biosynthesis:The formation of glycine from carbons 1 and 2 of 6-N-trimethyl-1-lysine.Biophys Res Commun,1976,70:364.
14 Ozorio,-R-O; Uktoseja,-J-L; Huisman,-E-A;et al. Changes in fatty acid concentrations in tissues of African catfish, Clarias gariepinus Burchell, as a consequence of dietary carnitine, fat and lysine supplementation. Br-J-Nutr. 2001 ; 86(5): 623-36.
15 Tran,-T-N; Christophersen,-B-O. Studies on the transport of acetyl groups from peroxisomes to mitochondria in isolated liver cells oxidizing the polyunsaturated fatty acid 22:4n-6. Biochim-Biophys-Acta. 2001 ; 1533(3): 255-65.
16 Borum PR.Variation in tissue carnitine concentrations with age and sex in the rat.Biochem J,1978,176:677.
17 顾天爵主编.生物化学.北京:人民卫生出版社,1998,183.
18 Carter AL,Rane Frenkel.The relationship of choline and carnitine in the choline deficient rat.J Nutr,1978.108:1748.
19 Tsai AC,Romsos DR,Leveille GA. Determination of carnitine turnover in choline-deficient and cold-exposed rats.J Nutr,1975,105:301.
20 任晓明.贝康停.中国新药杂志,2003,12(5):388-389.
21 Rudman D,Sewell CW,Ansley JD.Deficency of carnitine in cachectic cirrhotic patient.J Clin Invest,1977,60:716-723.
22 Selimoglu,-M-A; Yagci,-R-V. Plasma and liver carnitine levels of children with chronic hepatitis B. J-Clin-Gastroenterol. 2004 ; 38(2): 130-3.
23 Selimoglu,-M-A; Aydogdu,-S; Yagci,-R-V;et al.Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. Pediatr-Int. 2001 ; 43(4): 391-5.
24 张庭延.肉毒碱缺乏与临床.国外医学生理病理科学与临床分册,1992,1:24.
25 Owen,-K-Q; Jit,-H; Maxwell,-C-V;et al. Dietary L-carnitine suppresses mitochondrial branched-chain keto acid dehydrogenase activity and enhances protein accretion and carcass characteristics of swine. J-Anim-Sci. 2001 ; 79(12): 3104-12.
26 Karlic,-H; Lohninger,-S; Koeck,-T;et al. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J-Histochem-Cytochem. 2002 ; 50(2): 205-12.
27 Heo,-K; Lin,-X; Odle,-J;et al. Kinetics of carnitine palmitoyltransferase-I are altered by dietary variables and suggest a metabolic need for supplemental carnitine in young pigs. J-Nutr. 2000; 130(10): 2467-70.
28 赵芙,张相荛. 左旋肉硷对高脂血症的疗效. 广州医药,2000; 31(4):15 ~ 16.
29 Seccombe,-D-W; James,-L; Hahn,-P;et al. L-carnitine treatment in the hyperlipidemic rabbit. Metabolism. 1987 ; 36(12): 1192-6.
30 罗时敏,周凯,张天顺. 肉毒碱在肝硬化大鼠全胃肠外营养的应用. 实用医学杂志,2001; 17(6):481 ~ 482.
31 梁力建,罗时敏,郑进方,等.肉毒碱治疗 TPN 大鼠肝脂肪变性的研究.中华外科杂志,1999,37(8):500-503.
32 Hayashi,-Y; Muranaka,-Y; Kirimoto,-T;et al. Effects of MET-88, a gamma-butyrobetainehydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol-Pharm-Bull. 2000 ; 23(6): 770-3.
33 Arsland A,Lundquist M,Borretsen B,et al.On the effect of peroxisomal beta-oxidation and carnitine palmitoyl transferase activity by eicosapentaenoic acid in liver and heart rats.Lipids,1990,25:546.
34 Harper P,Wadstrom C,Backman L,et al. Increased liver carnitine content in obese women.Am J Nutr,1995,61:18.
35 冯宇,郭长江,韦京豫,等.半饥饿状态下高脂喂养对大鼠肉毒碱及脂类代谢的影响.中国临床营养杂志,2000 年 8(2):96-99.
36 冯 宇,郭长江,韦京豫,等.肉碱对高脂饲料喂养的半饥饿大鼠脂肪代谢的改善作用.中国病理生理杂志,2000,16(12):1313-1316.
37 Lapinski,-T-W; Grzeszczuk,-A.The impact of carnitine on serum ammonia concentration and lipid metabolism in patients with alcoholic liver cirrhosis. Pol-Merkuriusz-Lek.,2003 ,15(85): 38-41.
38 Bykov,-I; Jarvelainen,-H; Lindros,-K. L-carnitine alleviates alcohol-induced liver damage in rats: role of tumour necrosis factor-alpha.TNF. Alcohol-Alcohol. 2003 ; 38(5): 400-6.
39 Atila,-K; Coker,-A; Sagol,-O;et al. Protective effects of carnitine in an experimental ischemia-reperfusion injury. Clin-Nutr. 2002; 21(4): 309-13.
40 Spaniol,-M; Kaufmann,-P; Beier,-K;et al. Mechanisms of liver steatosis in rats with systemic CARNITINE deficiency due to treatment with trimethylhydraziniumpropionate. J-Lipid-Res. 2003; 44(1): 144-53.
41 Zeidan,-Q; Strauss,-M; Porras,-N; et al. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. J-Submicrosc-Cytol-Pathol. 2002 ; 34(3): 315-21.
42 赵虹,李彬祥,张利中,等. CT 定量诊断脂肪肝的实验研究. 中华放射学杂志,1997; 31(12):836 ~ 839
43 刘海峰,刘为纹. 影像学在脂肪肝诊断中的应用. 实用肝脏病杂志,1997; 2(3):135 ~ 136
44 程吉东,杨大男,李辉. 清肝合剂治疗酒精性脂肪肝 53 例. 中西医结合肝病杂志,2001; 11(4):241 ~ 242
45 王根生,韩哲武. 甘草类黄酮对四氯化碳致小鼠急性肝损伤的影响. 药学学报,1993; 28(8):575 ~ 576
46 庄婷婷,康素琼,俞晓芳. 甘利欣治疗慢性乙型肝炎 63 例. 福建中医药,2003; 34(4):30 ~ 31
47 张建,唐红敏,刘厚钰,等. 甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响. 肝脏,2003; 8(3):30 ~ 32
48 罗雁. 脂肪肝的研究进展. 医学综述,2003; 9(2):97 ~ 98
49 范建高,曾民德,李继强,等. Bezafibrate 对大鼠高脂血症和脂肪肝形成的影响. 胃肠病学和肝病学杂志,1999; 8(2):100 ~ 102
50 莫正纪. 左旋卡尼汀的药理学及其临床应用. 四川生理科学杂志,1997; 19(1):28
51 郑进方,梁力建.肉毒碱对全胃肠外营养大鼠肝损害的作用.中国临床药学杂志,2001; 10(1):31 ~ 34
1. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995, 19(suppl 1): S37 - S43.
2. Wang J, Chi DS, Kalin GB, et al. Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002, 47(1):107-113.
3. Eid R, Moss SF. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2002, 346(1):65-67.
4. International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994, 61:177-240.
5. Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol. 2003, 13(3):162-168.
6. Honda S, Fujioka T, Tokieda M, et al. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998, 58(19):4255-4259.
7. 郑青,陈晓宇,施尧,等. 幽门螺杆菌长期感染蒙古沙土鼠建立胃癌模型的研究. 中华消化杂志. 2003, 23(2):92-96.
8. 何兴祥,胡品津,Benjamin Chun Yu Wong,等. 幽门螺杆菌慢性感染诱导胃上皮细胞产生凋亡. 中华医学杂志. 2003, 83(1):42-45.
9. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001, 134(5):380-386.
10. Farinati F, Cardin R, Russo VM, et al. Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter. 2003, 8(3):227-234.
11. Tatemichi M, Hamada GS, Nishimoto IN, et al. Ethnic difference in serology of Helicobacter pylori CagA between Japanese and non-Japanese Brazilians for non-cardia gastric cancer. Cancer Sci. 2003, 94(1):64-69.
12. 张沥,张玲霞,张宁霞,等. 幽门螺杆菌细胞毒素相关蛋白 A 与胃癌关系的病例对照研究. 世界华人消化杂志. 2002, 10(5):593-595.
13. 宋春芳,孙丽萍,戴文颖,等. 幽门螺杆菌相关性胃疾病血清 IL-8 和 NO 含量的检测及意义. 中华肿瘤杂志. 2003, 25(3):258-260.
14. Bhattacharyya A, Pathak S, Datta S, et al. Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J. 2002, 368(Pt 1):121-129.
15. Kim JM, Kim JS, Jung HC, et al. Up-regulation of inducible nitric oxide synthase and nitric oxide in Helicobacter pylori-infected human gastricepithelial cells: possible role of interferon-gamma in polarized nitric oxide secretion. Helicobacter. 2002, 7(2):116-128.
16. 杜雅菊,赵晶,赵瑞波,等. 幽门螺杆菌 CagA 蛋白与胃癌组织中 Bcl-2、p53 蛋白表达的关系. 世界华人消化杂志. 2003, 11(5):554-557.
17. 刘海峰,刘为纹,房殿春,等. 根除幽门螺杆菌对胃癌前病变组织中 bax 蛋白表达的影响. 世界华人消化杂志. 2003, 11(1):22-24.
18. 陈孝,王孟薇,尤纬蒂. 胃粘膜上皮异型增生细胞增殖活性及凋亡与幽门螺杆菌感染的关系. 癌症. 2003, 22(3):244-247.
19. 李新华,张桂英,罗非君,等. 胃癌细胞系幽门螺杆菌感染对金属蛋白酶表达的影响.世界华人消化杂志. 2003, 11(5):544-546.
20. Tatsuguchi A, Sakamoto C, Wada K, et al. Localization of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut. 2000, 46(6):782-789.
21. Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000, 157(3):729-735.
22. Jackson LM, Wu KC, Mahida YR, et al. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut. 2000, 47(6):762-770.
23. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996, 270(3 Pt 1):G393-400.
24. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62(3):632-635.
25. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002, 196(2):171-179.
26. Konturek PC, Bielanski W, Konturek SJ, et al. Progastrin and cyclooxygenase-2 in colorectal cancer. Dig Dis Sci. 2002, 47(9):1984-1991.
27. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000, 118(3):487-496.
28. Gocyk W, Niklinski T, Olechnowicz H, et al. Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer. Med Sci Monit. 2000, 6(6):1085-1092.
29. Son HJ, Kim YH, Park DI, et al. Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer. J Clin Gastroenterol. 2001, 33(5):383-388.
30. 汪步海,汪竹,童建东,等. 环氧化酶-2 蛋白在胃癌患者肠上皮化生、异型增生及癌灶中的表达. 中华消化内镜杂志. 2003,20(3):179-181.
31. 王小虎,彭铁立,李胜保,等. 幽门螺杆菌与胃癌及癌前病变的环氧合酶-2 及 p21表达的研究. 实用肿瘤杂志. 2001,16(3):182-184.
32. Yamagata R, Shimoyama T, Fukuda S,et al. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol. 2002, 14(4):359-363.
33. Joo YE, Oh WT, Rew JS, et al. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002, 66(4):222-229.
34. Han SL, Tang HJ, Hua YW, et al. Expression of COX-2 in stomach cancers andits relation to their biological features. Dig Surg. 2003, 20(2):107-114.
35. 孔烨 韩少良 邵永孚,等. COX-2、p53、PCNA 和 nm23 异常表达与胃癌生物学行为的关系. 癌症. 2002,21(6):619-624.
36. 吴汉平,吴开春,幺立萍,等. 环氧合酶-2 反义核酸抑制胃癌细胞的恶性表型. 中华内科杂志. 2002,41(8):534-537.
37. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000, 30(1):3-21.
38. Kim JM, Kim JS, Jung HC, et al. Upregulated cyclooxygenase-2 inhibits apoptosis of human gastric epithelial cells infected with Helicobacter pylori. Dig Dis Sci. 2000, 45(12):2436-2443.
39. Balch CM, Dougherty PA, Cloud GA, et al. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 1984, 95(1):71-77.
40. Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003, 37(1):28-33.
41. 陶厚权,邹寿椿,王瑞年,等. 血管生成与胃癌发生之间关系的实验研究. 世界华人消化杂志. 2003,11(1):43-46.
42. McCarthy CJ, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999, 94(5):1218-1223.
43. 陆红,陈晓宇,刘文忠,等. 幽门螺杆菌感染对胃黏膜环氧化酶-2 表达的影响. 中华消化杂志. 2001,21(5):287-289.
44. Kimura A, Tsuji S, Tsujii M, et al. Expression of cyclooxygenase-2 and nitrotyrosine in human gastric mucosa before and after Helicobacter pylori eradication. Prostaglandins Leukot Essent Fatty Acids. 2000, 63(5):315-322.
45. Xiao F, Furuta T, Takashima M, et al. I Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. Aliment Pharmacol Ther. 2001, 15(6):875-886.
46. Romano M, Ricci V, Memoli A, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem. 1998, 273(44):28560-28563.
47. Kim JS, Kim JM, Jung HC, et al. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci. 2001, 46(10):2277-2284.
48. Guo XL, Wang LE, Du SY, et al. Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer. World J Gastroenterol. 2003, 9(2):246-249.
49. Chen CN, Sung CT, Lin MT, et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001, 233(2):183-188.
50. Konturek PC, Rembiasz K, Konturek SJ, et al. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci. 2003, 48(1):36-46.
51. Takahashi S, Fujita T, Yamamoto A. Role of cyclooxygenase-2 in Helicobacter pylori- induced gastritis in Mongolian gerbils. Am J Physiol Gastrointest Liver Physiol. 2000, 279(4):G791-798.
52. Kim H, Lim JW, Seo JY, et al. Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. J Environ Pathol Toxicol Oncol. 2002, 21(2):121-129.
53. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003, 63(13):3632-3636.
54. Feng L, Xia Y, Garcia GE, et al. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest. 1995, 95(4):1669-1675.
55. Konturek SJ, Konturek PC, Plonka A, et al. Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. Prostaglandins Other Lipid Mediat. 2001, 66(1):39-51.
56. Konturek PC, Kania J, Kukharsky V, et al. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol. 2003, 54(1):17-32.
57. Jones MK, Sasaki E, Halter F,et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J. 1999, 13(15):2186-2194.
58. Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 2001, 61(6):2399-24403.
59. Hmadcha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999, 190(11):1595-1604.
2 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊断标准.中华肝脏病杂志,2003; 11(2):71
3 范建高,曾民德. 非酒精性脂肪性肝病的分类及其诊断策略.中华肝脏病杂志,2003;11(2):127-128
4 Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999,107:450-455
5 Fan C-Y, Pan J, Usuda N, et al. Steatohepatitis,spontaneous peroxisone proliferation and liver tumours in mice prolixferatoractivated receptor alpha natural ligand metabolism.J Biol Chem,1998,273:15639-15645
6 Tokita H, Murai S, Kamitsukasa H, et al. In fluence of TT virus on the histopathological features of nonalcoholic fatty liver disease. Hepatol Res,2001,19(3):197-211
7 Tolba RH, Putz U, Decker D, et al. L-carnitine ameliorates abnormal vulnerability of steatotic rat livers to cold ischemic preservation. Transplantation, 2003; 76(12):1681 ~ 1686
8 杨丽蓉,徐晓玉. 甘利欣的药理作用与临床应用. 中国医院用药评价与分析,2003; 3(3):191 ~ 192
9 Furuno T, Kanno,Arita K,et al . Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem Pharmacol,2001;62(8):1037-1046.
10 Gulewitsch W,Krimberg R.Zur Kenntins der Extraktivstoffe der muskeln.Ueber bas Carnitin.Hoppe-Seyler’s Zeitschrift f.Physiol.Chemie,1905;45:326-330.
11 Frankel G. Caritine Book:Vitamin and Hormenes.Academic Press,New York,1957;XV:73-118.
12 Fritz IB.Carnitine and its Role in Fatty Acid Metabolism.Advances in Lipid Research,1963;285-334.
13 Hochalter JB.Carnitine biosynthesis:The formation of glycine from carbons 1 and 2 of 6-N-trimethyl-1-lysine.Biophys Res Commun,1976,70:364.
14 Ozorio,-R-O; Uktoseja,-J-L; Huisman,-E-A;et al. Changes in fatty acid concentrations in tissues of African catfish, Clarias gariepinus Burchell, as a consequence of dietary carnitine, fat and lysine supplementation. Br-J-Nutr. 2001 ; 86(5): 623-36.
15 Tran,-T-N; Christophersen,-B-O. Studies on the transport of acetyl groups from peroxisomes to mitochondria in isolated liver cells oxidizing the polyunsaturated fatty acid 22:4n-6. Biochim-Biophys-Acta. 2001 ; 1533(3): 255-65.
16 Borum PR.Variation in tissue carnitine concentrations with age and sex in the rat.Biochem J,1978,176:677.
17 顾天爵主编.生物化学.北京:人民卫生出版社,1998,183.
18 Carter AL,Rane Frenkel.The relationship of choline and carnitine in the choline deficient rat.J Nutr,1978.108:1748.
19 Tsai AC,Romsos DR,Leveille GA. Determination of carnitine turnover in choline-deficient and cold-exposed rats.J Nutr,1975,105:301.
20 任晓明.贝康停.中国新药杂志,2003,12(5):388-389.
21 Rudman D,Sewell CW,Ansley JD.Deficency of carnitine in cachectic cirrhotic patient.J Clin Invest,1977,60:716-723.
22 Selimoglu,-M-A; Yagci,-R-V. Plasma and liver carnitine levels of children with chronic hepatitis B. J-Clin-Gastroenterol. 2004 ; 38(2): 130-3.
23 Selimoglu,-M-A; Aydogdu,-S; Yagci,-R-V;et al.Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. Pediatr-Int. 2001 ; 43(4): 391-5.
24 张庭延.肉毒碱缺乏与临床.国外医学生理病理科学与临床分册,1992,1:24.
25 Owen,-K-Q; Jit,-H; Maxwell,-C-V;et al. Dietary L-carnitine suppresses mitochondrial branched-chain keto acid dehydrogenase activity and enhances protein accretion and carcass characteristics of swine. J-Anim-Sci. 2001 ; 79(12): 3104-12.
26 Karlic,-H; Lohninger,-S; Koeck,-T;et al. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J-Histochem-Cytochem. 2002 ; 50(2): 205-12.
27 Heo,-K; Lin,-X; Odle,-J;et al. Kinetics of carnitine palmitoyltransferase-I are altered by dietary variables and suggest a metabolic need for supplemental carnitine in young pigs. J-Nutr. 2000; 130(10): 2467-70.
28 赵芙,张相荛. 左旋肉硷对高脂血症的疗效. 广州医药,2000; 31(4):15 ~ 16.
29 Seccombe,-D-W; James,-L; Hahn,-P;et al. L-carnitine treatment in the hyperlipidemic rabbit. Metabolism. 1987 ; 36(12): 1192-6.
30 罗时敏,周凯,张天顺. 肉毒碱在肝硬化大鼠全胃肠外营养的应用. 实用医学杂志,2001; 17(6):481 ~ 482.
31 梁力建,罗时敏,郑进方,等.肉毒碱治疗 TPN 大鼠肝脂肪变性的研究.中华外科杂志,1999,37(8):500-503.
32 Hayashi,-Y; Muranaka,-Y; Kirimoto,-T;et al. Effects of MET-88, a gamma-butyrobetainehydroxylase inhibitor, on tissue carnitine and lipid levels in rats. Biol-Pharm-Bull. 2000 ; 23(6): 770-3.
33 Arsland A,Lundquist M,Borretsen B,et al.On the effect of peroxisomal beta-oxidation and carnitine palmitoyl transferase activity by eicosapentaenoic acid in liver and heart rats.Lipids,1990,25:546.
34 Harper P,Wadstrom C,Backman L,et al. Increased liver carnitine content in obese women.Am J Nutr,1995,61:18.
35 冯宇,郭长江,韦京豫,等.半饥饿状态下高脂喂养对大鼠肉毒碱及脂类代谢的影响.中国临床营养杂志,2000 年 8(2):96-99.
36 冯 宇,郭长江,韦京豫,等.肉碱对高脂饲料喂养的半饥饿大鼠脂肪代谢的改善作用.中国病理生理杂志,2000,16(12):1313-1316.
37 Lapinski,-T-W; Grzeszczuk,-A.The impact of carnitine on serum ammonia concentration and lipid metabolism in patients with alcoholic liver cirrhosis. Pol-Merkuriusz-Lek.,2003 ,15(85): 38-41.
38 Bykov,-I; Jarvelainen,-H; Lindros,-K. L-carnitine alleviates alcohol-induced liver damage in rats: role of tumour necrosis factor-alpha.TNF. Alcohol-Alcohol. 2003 ; 38(5): 400-6.
39 Atila,-K; Coker,-A; Sagol,-O;et al. Protective effects of carnitine in an experimental ischemia-reperfusion injury. Clin-Nutr. 2002; 21(4): 309-13.
40 Spaniol,-M; Kaufmann,-P; Beier,-K;et al. Mechanisms of liver steatosis in rats with systemic CARNITINE deficiency due to treatment with trimethylhydraziniumpropionate. J-Lipid-Res. 2003; 44(1): 144-53.
41 Zeidan,-Q; Strauss,-M; Porras,-N; et al. Differential long-term subcellular responses in heart and liver to adriamycin stress. Exogenous L-carnitine cardiac and hepatic protection. J-Submicrosc-Cytol-Pathol. 2002 ; 34(3): 315-21.
42 赵虹,李彬祥,张利中,等. CT 定量诊断脂肪肝的实验研究. 中华放射学杂志,1997; 31(12):836 ~ 839
43 刘海峰,刘为纹. 影像学在脂肪肝诊断中的应用. 实用肝脏病杂志,1997; 2(3):135 ~ 136
44 程吉东,杨大男,李辉. 清肝合剂治疗酒精性脂肪肝 53 例. 中西医结合肝病杂志,2001; 11(4):241 ~ 242
45 王根生,韩哲武. 甘草类黄酮对四氯化碳致小鼠急性肝损伤的影响. 药学学报,1993; 28(8):575 ~ 576
46 庄婷婷,康素琼,俞晓芳. 甘利欣治疗慢性乙型肝炎 63 例. 福建中医药,2003; 34(4):30 ~ 31
47 张建,唐红敏,刘厚钰,等. 甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响. 肝脏,2003; 8(3):30 ~ 32
48 罗雁. 脂肪肝的研究进展. 医学综述,2003; 9(2):97 ~ 98
49 范建高,曾民德,李继强,等. Bezafibrate 对大鼠高脂血症和脂肪肝形成的影响. 胃肠病学和肝病学杂志,1999; 8(2):100 ~ 102
50 莫正纪. 左旋卡尼汀的药理学及其临床应用. 四川生理科学杂志,1997; 19(1):28
51 郑进方,梁力建.肉毒碱对全胃肠外营养大鼠肝损害的作用.中国临床药学杂志,2001; 10(1):31 ~ 34
1. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995, 19(suppl 1): S37 - S43.
2. Wang J, Chi DS, Kalin GB, et al. Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig Dis Sci. 2002, 47(1):107-113.
3. Eid R, Moss SF. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2002, 346(1):65-67.
4. International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994, 61:177-240.
5. Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol. 2003, 13(3):162-168.
6. Honda S, Fujioka T, Tokieda M, et al. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998, 58(19):4255-4259.
7. 郑青,陈晓宇,施尧,等. 幽门螺杆菌长期感染蒙古沙土鼠建立胃癌模型的研究. 中华消化杂志. 2003, 23(2):92-96.
8. 何兴祥,胡品津,Benjamin Chun Yu Wong,等. 幽门螺杆菌慢性感染诱导胃上皮细胞产生凋亡. 中华医学杂志. 2003, 83(1):42-45.
9. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001, 134(5):380-386.
10. Farinati F, Cardin R, Russo VM, et al. Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter. 2003, 8(3):227-234.
11. Tatemichi M, Hamada GS, Nishimoto IN, et al. Ethnic difference in serology of Helicobacter pylori CagA between Japanese and non-Japanese Brazilians for non-cardia gastric cancer. Cancer Sci. 2003, 94(1):64-69.
12. 张沥,张玲霞,张宁霞,等. 幽门螺杆菌细胞毒素相关蛋白 A 与胃癌关系的病例对照研究. 世界华人消化杂志. 2002, 10(5):593-595.
13. 宋春芳,孙丽萍,戴文颖,等. 幽门螺杆菌相关性胃疾病血清 IL-8 和 NO 含量的检测及意义. 中华肿瘤杂志. 2003, 25(3):258-260.
14. Bhattacharyya A, Pathak S, Datta S, et al. Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J. 2002, 368(Pt 1):121-129.
15. Kim JM, Kim JS, Jung HC, et al. Up-regulation of inducible nitric oxide synthase and nitric oxide in Helicobacter pylori-infected human gastricepithelial cells: possible role of interferon-gamma in polarized nitric oxide secretion. Helicobacter. 2002, 7(2):116-128.
16. 杜雅菊,赵晶,赵瑞波,等. 幽门螺杆菌 CagA 蛋白与胃癌组织中 Bcl-2、p53 蛋白表达的关系. 世界华人消化杂志. 2003, 11(5):554-557.
17. 刘海峰,刘为纹,房殿春,等. 根除幽门螺杆菌对胃癌前病变组织中 bax 蛋白表达的影响. 世界华人消化杂志. 2003, 11(1):22-24.
18. 陈孝,王孟薇,尤纬蒂. 胃粘膜上皮异型增生细胞增殖活性及凋亡与幽门螺杆菌感染的关系. 癌症. 2003, 22(3):244-247.
19. 李新华,张桂英,罗非君,等. 胃癌细胞系幽门螺杆菌感染对金属蛋白酶表达的影响.世界华人消化杂志. 2003, 11(5):544-546.
20. Tatsuguchi A, Sakamoto C, Wada K, et al. Localization of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut. 2000, 46(6):782-789.
21. Sung JJ, Leung WK, Go MY, et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 2000, 157(3):729-735.
22. Jackson LM, Wu KC, Mahida YR, et al. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut. 2000, 47(6):762-770.
23. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol. 1996, 270(3 Pt 1):G393-400.
24. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62(3):632-635.
25. van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002, 196(2):171-179.
26. Konturek PC, Bielanski W, Konturek SJ, et al. Progastrin and cyclooxygenase-2 in colorectal cancer. Dig Dis Sci. 2002, 47(9):1984-1991.
27. Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000, 118(3):487-496.
28. Gocyk W, Niklinski T, Olechnowicz H, et al. Helicobacter pylori, gastrin and cyclooxygenase-2 in lung cancer. Med Sci Monit. 2000, 6(6):1085-1092.
29. Son HJ, Kim YH, Park DI, et al. Interaction between cyclooxygenase-2 and inducible nitric oxide synthase in gastric cancer. J Clin Gastroenterol. 2001, 33(5):383-388.
30. 汪步海,汪竹,童建东,等. 环氧化酶-2 蛋白在胃癌患者肠上皮化生、异型增生及癌灶中的表达. 中华消化内镜杂志. 2003,20(3):179-181.
31. 王小虎,彭铁立,李胜保,等. 幽门螺杆菌与胃癌及癌前病变的环氧合酶-2 及 p21表达的研究. 实用肿瘤杂志. 2001,16(3):182-184.
32. Yamagata R, Shimoyama T, Fukuda S,et al. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol. 2002, 14(4):359-363.
33. Joo YE, Oh WT, Rew JS, et al. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion. 2002, 66(4):222-229.
34. Han SL, Tang HJ, Hua YW, et al. Expression of COX-2 in stomach cancers andits relation to their biological features. Dig Surg. 2003, 20(2):107-114.
35. 孔烨 韩少良 邵永孚,等. COX-2、p53、PCNA 和 nm23 异常表达与胃癌生物学行为的关系. 癌症. 2002,21(6):619-624.
36. 吴汉平,吴开春,幺立萍,等. 环氧合酶-2 反义核酸抑制胃癌细胞的恶性表型. 中华内科杂志. 2002,41(8):534-537.
37. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000, 30(1):3-21.
38. Kim JM, Kim JS, Jung HC, et al. Upregulated cyclooxygenase-2 inhibits apoptosis of human gastric epithelial cells infected with Helicobacter pylori. Dig Dis Sci. 2000, 45(12):2436-2443.
39. Balch CM, Dougherty PA, Cloud GA, et al. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 1984, 95(1):71-77.
40. Joo YE, Rew JS, Seo YH, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol. 2003, 37(1):28-33.
41. 陶厚权,邹寿椿,王瑞年,等. 血管生成与胃癌发生之间关系的实验研究. 世界华人消化杂志. 2003,11(1):43-46.
42. McCarthy CJ, Crofford LJ, Greenson J, et al. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol. 1999, 94(5):1218-1223.
43. 陆红,陈晓宇,刘文忠,等. 幽门螺杆菌感染对胃黏膜环氧化酶-2 表达的影响. 中华消化杂志. 2001,21(5):287-289.
44. Kimura A, Tsuji S, Tsujii M, et al. Expression of cyclooxygenase-2 and nitrotyrosine in human gastric mucosa before and after Helicobacter pylori eradication. Prostaglandins Leukot Essent Fatty Acids. 2000, 63(5):315-322.
45. Xiao F, Furuta T, Takashima M, et al. I Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. Aliment Pharmacol Ther. 2001, 15(6):875-886.
46. Romano M, Ricci V, Memoli A, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem. 1998, 273(44):28560-28563.
47. Kim JS, Kim JM, Jung HC, et al. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci. 2001, 46(10):2277-2284.
48. Guo XL, Wang LE, Du SY, et al. Association of cyclooxygenase-2 expression with Hp-cagA infection in gastric cancer. World J Gastroenterol. 2003, 9(2):246-249.
49. Chen CN, Sung CT, Lin MT, et al. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma. Ann Surg. 2001, 233(2):183-188.
50. Konturek PC, Rembiasz K, Konturek SJ, et al. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. Dig Dis Sci. 2003, 48(1):36-46.
51. Takahashi S, Fujita T, Yamamoto A. Role of cyclooxygenase-2 in Helicobacter pylori- induced gastritis in Mongolian gerbils. Am J Physiol Gastrointest Liver Physiol. 2000, 279(4):G791-798.
52. Kim H, Lim JW, Seo JY, et al. Oxidant-sensitive transcription factor and cyclooxygenase-2 by Helicobacter pylori stimulation in human gastric cancer cells. J Environ Pathol Toxicol Oncol. 2002, 21(2):121-129.
53. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res. 2003, 63(13):3632-3636.
54. Feng L, Xia Y, Garcia GE, et al. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest. 1995, 95(4):1669-1675.
55. Konturek SJ, Konturek PC, Plonka A, et al. Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. Prostaglandins Other Lipid Mediat. 2001, 66(1):39-51.
56. Konturek PC, Kania J, Kukharsky V, et al. Influence of gastrin on the expression of cyclooxygenase-2, hepatocyte growth factor and apoptosis-related proteins in gastric epithelial cells. J Physiol Pharmacol. 2003, 54(1):17-32.
57. Jones MK, Sasaki E, Halter F,et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J. 1999, 13(15):2186-2194.
58. Akhtar M, Cheng Y, Magno RM, et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 2001, 61(6):2399-24403.
59. Hmadcha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med. 1999, 190(11):1595-1604.